147 related articles for article (PubMed ID: 2413022)
1. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin.
Salonen EM; Saksela O; Vartio T; Vaheri A; Nielsen LS; Zeuthen J
J Biol Chem; 1985 Oct; 260(22):12302-7. PubMed ID: 2413022
[TBL] [Abstract][Full Text] [Related]
2. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator.
Moser TL; Enghild JJ; Pizzo SV; Stack MS
J Biol Chem; 1993 Sep; 268(25):18917-23. PubMed ID: 8360181
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E.
Stewart RJ; Fredenburgh JC; Weitz JI
J Biol Chem; 1998 Jul; 273(29):18292-9. PubMed ID: 9660794
[TBL] [Abstract][Full Text] [Related]
4. Degradation of human plasma and extracellular matrix fibronectin by tissue type plasminogen activator and urokinase.
Marchina E; Barlati S
Int J Biochem Cell Biol; 1996 Oct; 28(10):1141-50. PubMed ID: 8930138
[TBL] [Abstract][Full Text] [Related]
5. Modulation of tissue plasminogen activator-catalyzed plasminogen activation by synthetic peptides derived from the amino-terminal heparin binding domain of fibronectin.
Stack MS; Pizzo SV
J Biol Chem; 1993 Sep; 268(25):18924-8. PubMed ID: 8360182
[TBL] [Abstract][Full Text] [Related]
6. Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators.
Lind SE; Smith CJ
Arch Biochem Biophys; 1993 Nov; 307(1):138-45. PubMed ID: 8239651
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
[TBL] [Abstract][Full Text] [Related]
9. Binding of tissue-type plasminogen activator to fibrinogen fragments.
Bosma PJ; Rijken DC; Nieuwenhuizen W
Eur J Biochem; 1988 Mar; 172(2):399-404. PubMed ID: 3127207
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
J Biol Chem; 1988 Dec; 263(35):19083-91. PubMed ID: 3143723
[TBL] [Abstract][Full Text] [Related]
11. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
12. Conversion of Glu-plasminogen to Lys-plasminogen is necessary for optimal stimulation of plasminogen activation on the endothelial cell surface.
Gong Y; Kim SO; Felez J; Grella DK; Castellino FJ; Miles LA
J Biol Chem; 2001 Jun; 276(22):19078-83. PubMed ID: 11264290
[TBL] [Abstract][Full Text] [Related]
13. Fibronectin decreases the stimulatory effect of fibrin and fibrinogen fragment FCB-2 on plasmin formation by tissue plasminogen activator.
Beckmann R; Geiger M; de Vries C; Pannekoek H; Binder BR
J Biol Chem; 1991 Feb; 266(4):2227-32. PubMed ID: 1824940
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
Hajjar KA; Hamel NM
J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of fibrin binding on the biochemical properties of single-chain tissue-type plasminogen activator (t-PA) and single-chain chimeric plasminogen activator (t-PA/scu-PA).
Fischer BE
Blood Coagul Fibrinolysis; 1992 Feb; 3(1):39-46. PubMed ID: 1320415
[TBL] [Abstract][Full Text] [Related]
16. Substrate specificity of tissue-type and urokinase-type plasminogen activators.
Rijken DC; Groeneveld E
Biochem Biophys Res Commun; 1991 Jan; 174(2):432-8. PubMed ID: 1899564
[TBL] [Abstract][Full Text] [Related]
17. Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin.
Silverstein RL; Harpel PC; Nachman RL
J Biol Chem; 1986 Jul; 261(21):9959-65. PubMed ID: 2942536
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody interferes with fibrin binding of t-PA.
Matsuo O; Okada K; Fukao H; Tanaka N; Ueshima S
Thromb Res; 1988 Sep; 51(5):485-94. PubMed ID: 2459803
[TBL] [Abstract][Full Text] [Related]
19. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen.
Hajjar KA
J Biol Chem; 1991 Nov; 266(32):21962-70. PubMed ID: 1657983
[TBL] [Abstract][Full Text] [Related]
20. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
